Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out

This publication has 11 references indexed in Scilit:

• Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
  Journal of Clinical Oncology, 2009
• Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime?
  European Journal Of Cancer, 2008
• Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
  Journal of Clinical Oncology, 2008
• HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy
  Journal of Clinical Oncology, 2008
• HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
  JNCI Journal of the National Cancer Institute, 2008
• HER2and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
  New England Journal of Medicine, 2006
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
  Oncogene, 1997
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994